Duan H, Liang L, Liu X, et al. - Researchers assessed the expression of pulmonary and activation-regulated chemokine (PARC)/CC-chemokine ligand 18 (CCL18) in chronic obstructive pulmonary disease (COPD) in this retrospective study including 98 hospitalized COPD patients as well as 60 healthy volunteers. A significantly higher level of serum PARC/CCL18 was found in hospitalized COPD population vs that in healthy people. A significantly higher serum level of PARC/CCL18 was detected in COPD patients with emphysema vs those without emphysema. There was a positive correlation of total lung capacity (TLC) and residual volume/TLC with serum concentration of PARC/CCL18. Findings demonstrated a link of PARC/CCL18 with the severity of inflammation as well as emphysema in COPD. It was also noted that inhaled corticosteroids application in the management of hospitalized COPD cases was predicted by PARC/CCL18.